NCT01460472Unknown3 期
A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy With Racotumomab Plus Best Support Treatment Versus Best Support Treatment in Patients With Advanced Non-small Cell Lung Camcer.
适应症
试验速览
- 阶段
- 3 期
- 发起方
- Recombio SL
- 入组人数
- 1,082
- 试验地点
- 48
- 主要终点
- Overall Survival
研究概览
简要总结
This is a prospective, randomized, open label, parallel-group, multicenter phase III study to evaluate the efficacy and safety of active specific immunotherapy with racotumomab plus best supportive care versus best supportive care in patients with advanced NSCLC who have achieved an Objective Response (Partial or Complete Response) or Stable Disease with standard first-line treatment. Also immunological parameters will be evaluated. Best supportive therapy will be administered to all patients in the study according to institutional standards and includes any subsequent onco-specific therapies. 1082 patients will be included in the study, with non-small cell lung cancer in stages IIIA (non-resectable), IIIB or IV.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily signed informed consent.
- •Cytologic or histologically diagnosed NSCLC in stages IIIA (non-resectable) or IIIB or IV (TNM).
- •In continuous complete or partial remission or stable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) after standard first-line treatment.
- •Imaging studies documenting the response to first-line therapy must be available for evaluation by the investigator.
- •Time lapse of 21 to 56 days between the end of onco-specific treatment and start of vaccination. Patients must have recovered from any acute toxicity produced by previous therapy.
- •Age greater than or equal to 18 years, either sex.
- •Eastern Cooperative Oncology Group performance status less than
- •Adequate organ function, defined as follows:
- •Electrocardiogram (ECG) without significant anomalies, performed in the 7 days preceding entry
- •Haemoglobin greater than or equal to 90 g/L
- •Total white blood cell count (WBC) greater than or equal to 3.0 x 10^9/L
- •Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
- •Platelet count greater than 100 x 10^9/L
- •Total bilirubin less than or equal to 1.5 fold the maximum normal value at the place of evaluation or 2.5 fold the maximum normal value in case of liver metastases
- •Glutamic-oxaloacetic transaminase/aspartate aminotransferase (GOT/AST), and glutamic-pyruvic transaminase/alanine aminotransferase (GPT/ALT), less than or equal to 2.5 fold the maximum normal value at the place of evaluation (in case of liver metastasis, less than 5 fold the maximum normal value)
- •Creatinine less than or equal to 2 mg/dL (less than or equal to 176 µmol/L)
- •Known hepatitis B virus carriers who have liver function tests within the accepted limits are eligible
排除标准
- •Pregnant or breastfeeding patients
- •Known hypersensitivity to any component of the formulation
- •Fertile patients of either sex who do not use adequate contraceptive methods while on treatment
- •Disease progression prior to randomization
- •Recurrent NSCLC, who relapse less than one year after completing curative intent therapy
- •Patients receiving other investigational medication (including investigational immunotherapy for NSCLC) or having received such medication within 30 days before entering the protocol
- •Autoimmune diseases or chronic decompensated diseases
- •Acute allergic disorders or a history of severe allergic reactions
- •Known brain metastases
- •History of demyelinating disease or inflammatory disease of the central nervous system or the peripheral nervous system
- •Non-controlled intercurrent diseases, including active infections, symptomatic congestive heart failure, unstable chest angina or heart arrhythmia, as well as mentally incapable patients
- •Other malignant diseases except non- melanoma skin cancer, in situ carcinoma of the cervix, incidental prostate cancer (T1a, Gleason less than or equal to 6, prostate specific antigen (PSA) less than 0.5 ng/ml) or any other tumour having received adequate treatment and evidencing a disease-free period greater than or equal to 5 years
- •Receiving chronic therapy for more than 10 days at doses of prednisone greater than 10 mg/day (or equivalent) at the moment of the inclusion. Inhaled and topical corticosteroids are allowed.
- •Active hepatitis C or positive tests for human immunodeficiency virus (HIV)
结局指标
主要结局
Overall Survival
时间窗: Until date of death or last censored observation, on average upto 17 months
A comparison of survival in the subgroup of inoperable stage IIIA and dry IIIB will be performed in 757 (approximately 70% of the study population)
次要结局
- Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside for Racotumomab Group(After the first year, every 3 months, on average for 17 months)
- Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay for Racotumomab Group.(Month 12)
- Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay for Best Support Treatment Group.(Month 4)
- Number of Participants with Adverse events as a measure of safety and tolerability(Until death, on average during 17 months)
- Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside(Baseline)
- Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.(Baseline)
- Evaluation of the reactivity if the antibodies against X63 tumor line (mouse myeloma) for Racotumomab Group(Month 12)
- Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside for Best Support Treatment Group(Month 4)
- Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.(Baseline)
- Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry in the Racotumomab Group.(Month 12)
- Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry in the Best Support Treatment Group.(Month 4)
- Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)(Baseline)
- Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) in the Racotumomab Group.(Month 12)
- Progression Free Survival(From randomization until date of first documented progression of disease, assessed as per RECIST 1.0 during an expected average of 17 months)
- Evaluation of the reactivity if the antibodies against X63 tumor line (mouse myeloma) for Best Support Treatment Group(Month 4)
- Evaluation of the reactivity if the antibodies against X63 tumor line (mouse yeloma) for Racotumomab Group(Month 3)
- Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) in the Best Support Treatment Group.(Month 4)
- Measurement of pro-inflammatory and anti-inflammatory cytokines(Baseline)
- Determination of anti-idiotypic IgG response in the Racotumomab Group.(Month 12)
- Measurement of pro-inflammatory and anti-inflammatory cytokines in the Racotumomab Group(Month 12)
- Measurement of pro-inflammatory and anti-inflammatory cytokines in the Best Support Treatment Group(Month 4)
- Determination of anti-idiotypic IgG response(Baseline)
- Determination of anti-idiotypic IgG response in the Best Support Treatment Group.(Month 4)
研究者
研究点 (48)
Loading locations...
相似试验
已完成
3 期
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial HypertensionNCT02932410Actelion165
已完成
3 期
A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital GonorrheaGonorrheaNCT04010539GlaxoSmithKline628
招募中
3 期
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLChronic Lymphocytic LeukemiaNCT05197192German CLL Study Group202
尚未招募
3 期
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsLocal Advanced or Metastatic NSCLCNCT06380348Shanghai JMT-Bio Inc.398
已完成
3 期
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaMultiple MyelomaNCT03110562Karyopharm Therapeutics Inc402